

## IHI Kick-off and brokerage event | 14 June 2022

### Speaker Bio



#### **Pierre Meulien**

#### **Executive Director Innovative Health Initiative**

Dr Pierre Meulien is Executive Director of the Innovative Health Initiative (IHI), a partnership between the European Union and Europe's health-related industries.

Dr Meulien has decades of experience in the life science sector, having worked in both the public and private sectors and on both sides of the Atlantic.

Having acquired a PhD in molecular biology from the University of Edinburgh, Scotland, he carried out a post-doctoral fellowship at the Institut Pasteur in Paris, France. He then moved to the private sector, working with the French biotechnology company Transgene, and Aventis Pasteur (now Sanofi Pasteur).

From 2002 to 2007, Dr Meulien served as founding CEO of the Dublin Molecular Medicine Centre which linked medical schools and teaching hospitals in Dublin to build a critical mass in molecular medicine and translational research.

From 2007 to 2010, he was Chief Scientific Officer at Genome British Columbia. In 2010 he became President and CEO of Genome Canada, where he raised significant funds for the organisation and oversaw the launch of novel projects and networks in the field of genomics-based technologies.

He returned to Europe in 2015 to take up the post of Executive Director of the Innovative Medicines Initiative (IMI), the fore runner of IHI. In that role, he brought new partners into the organisation, including philanthropic organisations and companies. He also oversaw the launch of wide-ranging programmes on big data, neurological conditions, and antimicrobial resistance, as well as a rapidly-launched portfolio of projects on COVID diagnostics and treatments, all of which have had global reach.

More recently, he led the organisation throughout the transition from IMI to IHI.

Dr Meulien has Irish nationality.

